Aphria Inc. (TSX: APH) (US OTC: APHQF) today announced that it has signed an exclusive supply agreement with Colcanna SAS a Colombia-based pharmaceutical import and distribution company, which is licensed to import, sell and distribute medical cannabis, medical products and derivatives in Colombia.

“We see tremendous potential for medical cannabis in several emerging markets, including Colombia,” said Vic Neufeld, CEO of Aphria. “We are thrilled to enter the Colombian-market through this exclusive agreement with Colcanna. Aphria will continue to expand its global leadership through strategic investments, partnerships and agreements such as this one.”

Under the terms of the agreement, Aphria will be the exclusive supplier of cannabis products to Colcanna for the Colombian market and Colcanna will purchase medical cannabis products from Aphria exclusively. At the importer’s request, financial terms of the agreement are not being released.

About Aphria

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.